The power of ribozyme technologies: The logical way ahead for molecular medicine and gene therapy?

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 5, 2002, Pages 419-422

  Freelove, Alexander C J ^a   Zheng, Richard ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cancer; Gene therapy; Hammerhead ribozyme; Ribozyme; RNA

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOZYME; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CONSENSUS INTERFERON; HAMMERHEAD RIBOZYME; HEPTAZYME; HERZYME; LIPOSOME; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RIBONUCLEASE P; RIBOZYME; RNA; RNA HELICASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VIRUS RNA;

ALLERGY; AUTOIMMUNE DISEASE; BIOTECHNOLOGY; BLADDER CANCER; BLOOD CLOTTING DISORDER; BREAST CANCER; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INHIBITION KINETICS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; RAT; RETINITIS PIGMENTOSA; REVIEW; RNA CLEAVAGE; RNA TRANSLATION; TARGET CELL; TREATMENT FAILURE; TUMOR GROWTH;

AUTOIMMUNE DISEASES; GENE THERAPY; GENETIC DISEASES, INBORN; HUMANS; HYPERSENSITIVITY; NEOPLASMS; RNA, CATALYTIC; VIRUS DISEASES;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0036819772     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Cech TR, Zaug AJ, Grabowski PJ: In vitro splicing of the ribosomal RNA precursor of Tetrahymena: Involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell (1981) 27:487-496.
2. Guerrier-Takada C, Gardiner K, Marsh T, Pace N, Altman S: The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell (1983) 35:849-857.
3. Lewin AS, Hauswirth WW: Ribozyme gene therapy: Applications for molecular medicine. Trends Mol Med (2001) 7(5):221-228.
4. Doherty EA, Doudna JA: Ribozyme structures and mechanisms. Annu Rev Biophys Biomol Struct (2001) 30:457-475.
5. Branch AD, Robertson HD: A replication cycle for viroids and other small infectious RNA's. Science (1984) 223:450-455.
6. Fedor MJ: The role of metal ions in RNA catalysis. Curr Opin Struct Biol (2002) 12(3):289-295.
7. Doudna JA, Cech TR: The chemical repertoire of natural ribozymes. Nature (2002) 418:222-228.
8. Lebruska LL, Kuzmine II, Fedor MJ: Rescue of an abasic hairpin ribozyme by cationic nucleobases. Evidence for a novel mechanism of RNA catalysis. Chem Biol (2002) 9(4):465-473.
9. Warashina M, Kuwabara T, Kato Y, Sano M, Taira K: RNA-protein hybrid ribozymes that efficiently cleave any mRNA independently of the structure of the target RNA. Proc Natl Acad Sci USA (2001) 98(10):5572-5577.
10. Kawasaki H, Onuki R, Suyama E, Taira K: Identification of genes that function in the TNF-α-mediated apoptotic pathway using randomized hybrid ribozyme libraries. Nat Biotechnol (2002) 20(4):376-380.
11. Usman N, Blatt LM: Nuclease-resistant synthetic ribozymes: Developing a new class of therapeutics. J Clin Invest (2000) 106(10):1197-1202.
12. Clinical Programs. Ribozyme Pharmaceuticals Inc, CO, USA (2002). http://www.rpi.com/clinical.jsp.
13. Ribozyme Pharmaceuticals announces clinical trials update and conference call. PR Newswire, NY, USA (April 30 2002). http://www.prnewswire.com/micro/RZYM.
14. Ribozyme Pharmaceuticals announces ANGIOZYME metastatic colorectal open-label phase II clinical trial update. PR Newswire, NY, USA (June 10 2002). http://www.prnewswire.com/micro/RZYM.
15. Irie A, Kashani-Sabet M, Scanlon KJ, Uchida T, Baba S: Hammerhead ribozymes as therapeutic agents for bladder cancer. Mol Urol (2000) 4(2):61-66.
16. Kobayashi H, Takemura Y, Miyachi H: Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics. Hum Cell (2001) 14(3):172-184.
17. Kowalski P, Stein U, Scheffer GL, Lage H: Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther (2002) 9(7):579-586.
18. Tani M, Goto S, Kamada K, Mori K, Urata Y, Ihara Y, Kijima H, Ueyama Y, Shibata S, Kondo T: Hammerhead ribozyme against γ-glutamylcysteine synthetase attenuates resistance to ionizing radiation and cisplatin in human T98G glioblastoma cells. Jpn J Cancer Res (2002) 93(6):716-722.
19. Tanaka M, Kijima H, Itoh J, Matsuda T, Tanaka T: Impaired expression of a human septin family gone Bradeion inhibits the growth and tumorigenesis of colorectal cancer in vitro and in vivo. Cancer Gene Ther (2002) 9(6):483-488.
20. Macejak DG, Jensen KL, Jamison SF, Domenico K, Roberts EC, Chaudhary N, von Carlowitz I, Bellon L, Tong MJ, Conrad A, Pavco PA et al: Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology (2000) 31(3):769-776.
21. Ramezani A, Ma XZ, Nazari R, Joshi S: Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1. Front Bioscience (2002) 7:e29-e36.
22. Farrar GJ, Kenna PF, Humphries P: On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J (2002) 21(5):857-864.
23. Hu WY, Fukuda N, Kotani M, Kanmatsuse K: Adenovirus-mediated transfer of ribozyme targeting platelet-derived growth factor A-chain mRNA inhibits growth of vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol (2002) 39(6):858-865.
24. Cavusoglu E, Chen I, Rappaport J, Marmur JD: Inhibition of tissue factor gene induction and activity using a hairpin ribozyme. Circulation (2002) 105(19):2282-2287.
25. Takahashi M, Funato T, Suzuki Y, Fujii H, Ishii KK, Kaku M, Sasaki T: Chemically modified ribozyme targeting TNF-α mRNA regulates TNF-α and IL-6 synthesis in synovial fibroblasts of patients with rheumatoid arthritis. J Clin Immunol (2002) 22(4):228-236.